What is AGMB's market cap?

$313.22M, based on the Nov 12 close of $6.36.

NASDAQ · AGMB

AgomAb Therapeutics NV American Depositary Shares (AGMB)

$6.36−9.01%

Close Nov 12, 2026 · split-adjusted

Nov 9, 2026$7.55▼ 48.46% in range

Feb 6, 2026Low $6.72 · High $17.82Nov 9, 2026

What changed · written from our data

As of Nov 12, 2026

AgomAb Therapeutics NV American Depositary Shares closed at $6.36 on Nov 12, down 9.01%, within 0.0% of its lowest close since Feb 6. Volume of 1.5M shares was 7.25× its 20-day average (well above normal).

Split-adjusted performance: -26.8% over one month, -42.4% over six months.

Short interest was 920.9K shares at the Oct 30 settlement, down 2.2% from the prior report (7.4 days to cover).

Market cap$313.2M49.2M shares

Revenue · quarter——

Diluted EPS——

P/E · TTM—

Net margin—

Dividend yieldNone

Range since Feb 66.36 – 17.82−64.3% from high

Volume1.5M7.25× 20-day avg

Volatility · 60d84.5%Annualised

Short % of float—7.4 days to cover

Net cash—

Next earnings—Not scheduled

Split-adjusted performance

1W −8.8%1M −26.8%3M −51.9%6M −42.4%YTD —1Y —3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within industry

Not enough peers to rank

6-month momentum—

Revenue growth—

Net margin—

Value (low P/E)—

Size—

Short interest

Details →

Shares short920.9K−2.2% vs prior

Days to cover7.4Settled Oct 30

% of float—

Short vol. 10d28.1%of daily volume

News about AgomAb Therapeutics NV

All news →

Agomab Announces Results of Annual General MeetingGlobeNewswire Inc. · May 27, 2026Neutral Agomab Reports Full Year 2025 Financial Results and Confirms 2026 OutlookGlobeNewswire Inc. · Apr 23, 2026▲ Positive Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary FibrosisGlobeNewswire Inc. · Mar 26, 2026▲ Positive

Quick answers

What does AgomAb Therapeutics NV American Depositary Shares do?: AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches.
What is AGMB's market cap?: $313.22M, based on the Nov 12 close of $6.36.

About AgomAb Therapeutics NV

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.

62 employeesListed Feb 6, 2026agomab.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology